EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm

Nazile Bilgin Dogan, Hamiyet Yilmaz Yasar, Baris Kilicaslan

Texas Heart Institute Journal · 06.12.2023 · 50 (6)

DOI: 10.14503/thij-23-8196 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Texas Heart Institute Journal, erschienen am 06.12.2023. Verfasst von Nazile Bilgin Dogan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Updated recommendations for the treatment of heart failure with reduced ejection fraction (HFrEF) include sodium-glucose cotransporter 2 (SGLT2) inhibitors and other long-established HFrEF therapies. These drugs’ mechanisms of action have yet to be fully clarified.

Objective

This study evaluated the effects of SGLT2 inhibitors on the modulation of autonomic function at 1 month beyond conventional HF therapy.

Methods

This single-center, observational, prospective study was conducted from January 2020 to December 2022. Patients with type 2 diabetes who had ischemic HFrEF and met the study criteria were considered for SGLT2 inhibitor treatment with empagliflozin or dapagliflozin. Changes in the circadian index were used as the primary outcome to assess the early effects of SGLT2 inhibitors on autonomic function. Changes in functional effort capacity and laboratory findings were also evaluated. Participants’ circadian index was measured by a 24-hour rhythm Holter monitoring recorder (BTL-08 Holter H100). A symptom-limited treadmill test assessed patients’ effort capacities. Tests were repeated after 1 month of therapy.

Results

The mean (SD) age of the 151 participants was 56.95 (7.29) years; their mean (SD) left ventricular EF was 35.69% (7.10%), and 95 participants were men (62.9%). From baseline to 1 month, mean (SD) daytime heart rate (80.63 [9.17] vs 77.67 [8.04] beats per minute; P = .004) and nighttime heart rate (76.83 [11.34] vs 73.81 [10.25] beats per minute; P = .03) decreased significantly. Variation in the circadian indexes (mean [SD], 1.04 [0.02] vs 1.10 [0.04]; P < .001) was statistically significant, favoring increased modulation of autonomic function. The increases in exercise duration (mean [SD], 8.88 [3.69] minutes and median [IQR], 8.81 [5.76-12.13] minutes vs 9.72 [3.14] and 9.59 [7.24-12.22] minutes; P = .04) and exercise capacity (mean [SD], 203.38 [65.18] m and median [IQR], 119.22 [149.43-259.15] m vs 335.61 [51.39] and 325.79 [293.59-376.91] m; P < .001] were also significant.

Conclusion

The use of SGLT2 inhibitors during early treatment can favorably affect both autonomic dysfunction and functional effort capacity of patients with type 2 diabetes with ischemic HFrEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHeart FailureMaleHumansMiddle AgedFemaleProspective StudiesStroke VolumeGlucoseSodium

Stichwörter der Autor:innen

Heart failureheart ratephysical exertionreduced ejection fractionsodium-glucose transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGlucoseSodium

Autor:innen und Institutionen

  • Department of Cardiology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey.
  • Department of Endocrinology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey.

Zitieren

APA

Dogan, N. B., Yasar, H. Y., & Kilicaslan, B. (2023). Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm. Texas Heart Institute Journal, 50(6). https://doi.org/10.14503/thij-23-8196

Vancouver

Dogan NB, Yasar HY, Kilicaslan B. Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm. Texas Heart Institute Journal. 2023;50(6). doi:10.14503/thij-23-8196

BibTeX
@article{Dogan2023,
  author = {Dogan, Nazile Bilgin and Yasar, Hamiyet Yilmaz and Kilicaslan, Baris},
  title = {Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm},
  journal = {Texas Heart Institute Journal},
  year = {2023},
  volume = {50},
  number = {6},
  doi = {10.14503/thij-23-8196}
}
Kostenlos starten →